Accessibility / Report Error

Imunogenicidade da cepa avirulenta RV194-2 do vírus rábico em camundongos

Resumos

O vírus rábico RV194-2, uma variante avirulenta da cepa CVS (Challenge Vírus Standard), produz uma infecção inaparente quando inoculado intracerebralmente em camundongos adultos. Sugerindo que a resposta imunológica do hospedeiro permite a eliminação do vírus do sistema nervoso central. Por esta razão foram estudadas a indução de interferon e a resposta imune humoral em camundongos BALB/c inoculados com vírus RV194-2. Durante a infecção, estes camundongos apresentaram elevados níveis de interferon no plasma e no cérebro com altos títulos de anticorpos neutralizantes anti-rábicos. A 2-5A sintetase. um marcador da ação dos interferons,foi também analisada no cérebro destes animais. Sua atividade, aumentou, paralelamente, á produção de interferon, demonstrando que este interferon é bioquímicamente ativo. O vírus RV194-2 também induziu, 45 dias após sua inoculação, proteção aos animais quando desafiados com a cepa virulenta CVS. Estes resultados demonstram que a cepa RV194-2possui um alto nível imunogênico.

Vírus rábico; Interferon; Imunogenicidade


RV194-2 rabies virus, an avirulent mutant of CVS strain, induces an inapparent infection limited to the central nervous system (CNS) in adult mice inoculated intracerebrally. This fact suggest that immune response of the host is able to eliminate the virus in CNS. For this reason, we have studied the induction of interferon and the humoral immune responses in BALB/c mice after RV194-2 inoculation. These mice presented high levels of interferon in the plasma and in the brain, with elevated levels of neutralizing antirabies antibodies. The 2-5A synthetase, an enzyme marker of interferon action, was analyzed in the brain of inoculated animals. Its enhancement in parallel to the interferon production in the brain, showed biochemical evidence that this interferon is active. Forty five days after RV194-2 virus inoculation, mice were protected against a challenge with the CVS virulent strain. The results presented herein show that RV194-2 strain has a bigh level of immunogenicity.

Rabies virus; Interferon; Immunogenicity


ARTIGOS

Imunogenicidade da cepa avirulenta RV194-2 do vírus rábico em camundongos

Rugimar Marcovistz; Eduardo Chaves Leal; Denise Cristina S. de Matos; Humberto Pinheiro de Araújo; Henri Tsiang

Endereço para correspondência Endereço para correspondência: Dra. Rugimar Marcovistz. Serviço de Controle de Qualidade, Instituto Butantan. Av. Brasil 1500, Butantan 05503-900, São Paulo, Brasil.

RESUMO

O vírus rábico RV194-2, uma variante avirulenta da cepa CVS (Challenge Vírus Standard), produz uma infecção inaparente quando inoculado intracerebralmente em camundongos adultos. Sugerindo que a resposta imunológica do hospedeiro permite a eliminação do vírus do sistema nervoso central. Por esta razão foram estudadas a indução de interferon e a resposta imune humoral em camundongos BALB/c inoculados com vírus RV194-2. Durante a infecção, estes camundongos apresentaram elevados níveis de interferon no plasma e no cérebro com altos títulos de anticorpos neutralizantes anti-rábicos. A 2-5A sintetase. um marcador da ação dos interferons,foi também analisada no cérebro destes animais. Sua atividade, aumentou, paralelamente, á produção de interferon, demonstrando que este interferon é bioquímicamente ativo. O vírus RV194-2 também induziu, 45 dias após sua inoculação, proteção aos animais quando desafiados com a cepa virulenta CVS. Estes resultados demonstram que a cepa RV194-2possui um alto nível imunogênico.

Palavras-chaves: Vírus rábico. Interferon. Imunogenicidade.

ABSTRACT

RV194-2 rabies virus, an avirulent mutant of CVS strain, induces an inapparent infection limited to the central nervous system (CNS) in adult mice inoculated intracerebrally. This fact suggest that immune response of the host is able to eliminate the virus in CNS. For this reason, we have studied the induction of interferon and the humoral immune responses in BALB/c mice after RV194-2 inoculation. These mice presented high levels of interferon in the plasma and in the brain, with elevated levels of neutralizing antirabies antibodies. The 2-5A synthetase, an enzyme marker of interferon action, was analyzed in the brain of inoculated animals. Its enhancement in parallel to the interferon production in the brain, showed biochemical evidence that this interferon is active. Forty five days after RV194-2 virus inoculation, mice were protected against a challenge with the CVS virulent strain. The results presented herein show that RV194-2 strain has a bigh level of immunogenicity.

Keywords: Rabies virus. Interferon. Immunogenicity.

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

14. Isaacs A, Burke DC. Viral interference and interferon 15:185-188,1959.

Recebido para publicação em 01/09/95.

  • 1. Atanasiu P. Role de l'interferferferon dans l'immunité antirabique. Compendium of Immunology and Microbiology of Infectious Diseases. 5:123-127,1982.
  • 2. Baer GM, Yager PA. A mouse model for rabies post-exposure rabies prophylaxis. Comparative efficacy of vaccine and the antiserum administration. Journal of General Virology 36:51- 57,1977.
  • 3. Buffet-Janvresse C, Magared H, Robert N, Hovanessian AG. Assay and levels of 2-5A synthetase in lymphocytes of patients with viral, bacterial and auto immune diseases. Annalles de Immunologie (Institut Pasteur) 134D:247-258, 1983.
  • 4. Coulon i; Derbin C, Kucera P La Fay J; Prehaud C, Flamand A. Invasion of the peripheral nervous system of adult mice by the CVS strain of rabies virus and avirulent derivative AQV01. Journal of Virolology 63:3550-3554,1989.
  • 5. Coulon P, Rollin P, Aubert M, Flamand A. Moleculare basis of rabies virulence. I. Selection of avirulent mutants of the CVS strain of rabies virus with anti-G monoclonal antibodies. Journal of General Virology 61:97-100,1982a.
  • 6. Coulon P, Rollin P, Blancou J, Flamand A. Avirulent mutant of CVS strain of rabies virus. Compendium of Immunology and Microbiology Infectious Disease 5:117-122,1982b.
  • 7. Coulon P, Rollin P., Flamand A. Molecular basis of rabies virulence. II. Indentification of a site on the CVS glycoprotein associated with virulence. Journal of General Virology 64:693-696,1983.
  • 8. Dietzschold B, Wiktor JT, Trojanowski JQ, Macfarlan RI Wunner WH, Torres-Angel MJ Koprowski H. Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo an in vitroJournal of Virology 56:12-18,1985.
  • 9. Dietzschold B, Wunner WH, Wiktor TJ, Lopes AD, Lafon M, Smith CL, Koprowski H. Characterization of an antigenic determinant of glycoprotein that correlates with pathogenicity of rabies virus. Proceedings of National Academy of Sciences 80:70-74,1983.
  • 10. Famand A, Wiktor TJ, Koprowisk H. Use of hybridoma monoclonal antibodies in the detection of antigenic differences between rabies and rabies related virus protein. II. The glicoprotein. Journal of General Virology 48:105- 109,1980.
  • 11. Galabru J, Robert N, Buffet-Janvresse C, Rivière YL, Hovanessian AG. Continuous production of interferon in normal mice: Effect of anti interferon globtilin, sex, age, strain and inviromment on the levels of 2-5A synthetase and pG7k kinase. Journal of General Virology 66:711- 718,1985.
  • 12. Hillman MR. Interferon induction and utilization. Journal of Cell Physiology 71:43-60, 1968.
  • 13. Hovanessian AG, Rivière Y. Interferon-mediated induction of 2-5A synthetase and protein in the liver and spleen of mice infected with New Castle disease virus as injected with poly (I), poly (C). Annalles de Virologie (Institut Pasteur) 131E:501-516,1980.
  • 15. Isaacs A, Lindenmann J. Virus interference. I. the interferon. II. Some properties of interferon. Proceedings of Royal Society of Medicine l47B:258-267,1957.
  • 16. Jackson AC. Biological basis of rabies virus neurovirulence in mice: Comparative pathogenesis study using the immunoperoxidase technique. Journal ofVirology 65:537-540,1991.
  • 17. Jackson AC, Reimer DL. Pathogenesis of experimental rabies in mice: an immimohistochemical study. Acta Neuropathologica 78:159-165,1989.
  • 18. Kucera P, Dolivo M, Coulon P, Flamand A. Pathways of the early propagation of virulent and avirulent rabies strain from the eye to the brain. Journal ofVirology 55:158-162,1985.
  • 19. Lodmell DL, Wildbrank DL, Ewalt LC. Interferon induced within the central nervous system during infection is in consequencial as a mechanism responsible for murine resistence to street rabies virus. Journal of General Virology 70:473-478,1989.
  • 20. Marcovistz R, Galabru J,Tsiang H, Hovanessian AG, Neutralization of interferon produced early during rabies virus infection in mice. Journal of General Virology 67:387-390,1986.
  • 21. Marcovistz R, Germano PML, Tsiang H, Hovanessian AG. The effect of interferon treatment in rabies prophylaxis in immunocompetent, immunosuppressed and immunodeficient mice. Journal of Interferon Research 7:17-27,1987.
  • 22. Marcovistz R, Tsiang H, Hovanessian AG. Prodoction and action of interferon in mice infected with rabies virus.Annalles de Virologie (Inst Pasteur) 135E:19-33,1984.
  • 23. Reagan KJ, Wunner WH, Wiktor TJ, Koprowski H. Anti-idiotipic antibodies induce neutralizing antibodies to rabies virus glycoprotein. Journal of Virology 48:660-666,1983.
  • 24. Tuffereau C, Lebois H, Benejean J, Coulon P, Lafay F, Flamand A. Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virology 172:206-212, 1989.
  • 25. Wiktor TJ, Clark HF. Comparation of rabies virus strains by means of plaque reduction test. Annalles de Microbiologie (Institut Pasteur) 124A:283-287,1973.
  • 26. Wiktor TJ, Koprowski H. Monoclonal antibody against rabies virus produced by somatic cell hybridization: Detection of antigenic variants. Proceedings of National Academy of Sciences (USA). 75:3938-3942,1978.
  • 27. Wiktor TJ, Koprowski H. Antigenic variants of rabies virus. Journal of Experimental Medicine 152:99-112,1980.
  • 28. Witaker RJ, Granun PE. An absolute methods for protein determination based on difference in absorbance at 235 and 280 nm. Annals of Biochemistry 109:156-159,1980.
  • Endereço para correspondência:

    Dra. Rugimar Marcovistz.
    Serviço de Controle de Qualidade, Instituto Butantan.
    Av. Brasil 1500, Butantan
    05503-900,
    São Paulo, Brasil.
  • Datas de Publicação

    • Publicação nesta coleção
      04 Abr 2013
    • Data do Fascículo
      Dez 1996

    Histórico

    • Recebido
      01 Set 1995
    • Aceito
      01 Set 1995
    Sociedade Brasileira de Medicina Tropical - SBMT Caixa Postal 118, 38001-970 Uberaba MG Brazil, Tel.: +55 34 3318-5255 / +55 34 3318-5636/ +55 34 3318-5287, http://rsbmt.org.br/ - Uberaba - MG - Brazil
    E-mail: rsbmt@uftm.edu.br